title: Selectively expanding subsets of T cells in mice by injection of interleukin-2/antibody complexes: implications for transplantation tolerance.
abstract: The biological activity of interleukin (IL)-2 and other cytokines in vivo can be augmented by binding to certain anti-cytokine monoclonal antibodies (mAb). Here, we review evidence on how IL-2/anti-IL-2 mAb complexes can be used to cause selective stimulation and expansion of certain T-cell subsets. With some anti-IL-2 mAbs, injection of IL-2/mAb complexes leads to expansion of CD8 T effector cells but not CD4 T regulatory cells (Tregs); these complexes exert less adverse side effects than soluble IL-2 and display powerful antitumor activity. Other IL-2/mAb complexes have minimal effects on CD8 T cells but cause marked expansion of Tregs. Preconditioning mice with these complexes leads to permanent acceptance of MHC-disparate pancreatic islets in the absence of immunosuppression.
authors.affiliation: Laboratory of Applied Immunobiology, University of Zurich, Zurich, Switzerland.
authors.forename: O
authors.initials: O
authors.lastname: Boyman
authors.forename: C
authors.initials: C
authors.lastname: Krieg
authors.forename: S
authors.initials: S
authors.lastname: Letourneau
authors.forename: K
authors.initials: K
authors.lastname: Webster
authors.forename: C D
authors.initials: CD
authors.lastname: Surh
authors.forename: J
authors.initials: J
authors.lastname: Sprent
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage; D049109:Cell Proliferation; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control; D006085:Graft Survival; D006648:Histocompatibility; D007267:Injections; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000276:immunology; D016381:Islets of Langerhans Transplantation / Q000276:immunology*; D008213:Lymphocyte Activation; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D019172:Transplantation Conditioning / Q000379:methods*; D023001:Transplantation Tolerance
chemical_list: D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; D007376:Interleukin-2